Evidence map›Paper›PMID 42205796›Full record

ArticleESMO gastrointestinal oncology2026

A phase II study of pembrolizumab plus chemotherapy with short-course radiotherapy as induction treatment for unresectable locally advanced esophageal squamous cell carcinoma: PALADIN trial.

D Okemoto, D Kotani, M Nakamura, K Sato, Y Kubo, T Kadota, S Mishima, S Sakashita, T Hashimoto, H Bando and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

D OkemotoDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
D KotaniDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
M NakamuraDepartment of Radiation Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
K SatoDivision of Esophageal Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Y KuboDivision of Esophageal Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
T KadotaDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan.
S MishimaDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
S SakashitaDepartment of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.
T HashimotoDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
H BandoDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
M WakabayashiDepartment for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa, Japan.
M RabinowitzNatera, Inc., Austin, USA.
M C LiuNatera, Inc., Austin, USA.
A JurdiNatera, Inc., Austin, USA.
T YamaguchiSecond Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
H NishikawaSecond Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
K ShitaraDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
T YanoDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan.
T KojimaDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Takeo FujitaDivision of Esophageal Surgery, National Cancer Center Hospital East, Kashiwa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Definitive chemoradiotherapy is a standard treatment for unresectable locally advanced esophageal squamous cell carcinoma (LAESCC), but complete response rates remain 15%-25%, and median overall survival (OS) is 13-14 months. More effective strategies are needed. Trial design: The PALADIN trial is a nonrandomized, single-arm phase II study evaluating the efficacy and safety of induction pembrolizumab plus chemotherapy with short-course radiotherapy (SCRT) in unresectable LAESCC. Eligible patients have confirmed squamous cell carcinoma with T3br-T4b (Japanese Classification of Esophageal Cancer, 12th edition). Treatment consists of pembrolizumab 200 mg and cisplatin 80 mg/m

Indexed as

induction treatmentpembrolizumab plus chemotherapy with short-course radiotherapyunresectable locally advanced esophageal squamous cell carcinoma

Identifiers

PMID42205796
PMCPMC13202593

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.